Eur J Cancer: The actual clinical efficacy of olaparib monotherapy in the treatment of gBRCAm-HER2-negative metastatic breast cancer

In the Phase III OlympiAD trial, olaparib significantly prolonged the progression-free progression of human epidermal growth factor 2 (HER2) negative metastatic breast cancer (mBC) patients with BRCA germline mutation (gBRCAm) compared with the chemotherapy determined by the doctor Lifetime (PFS)

The Phase IIIb LUCY trial aims to evaluate the clinical effectiveness of olapa in similar patients in an environment that reflects clinical practice

The LUCY trial is an open-label, single-arm clinical trial that recruits BRCAm and HER2-negative mBC patients who have previously received taxane and/or anthracycline therapy under (new) adjuvant/metastatic conditions, and targeted There is no more chemotherapy for mBC than second-line chemotherapy

PFS of the entire queue

Of the 563 patients screened , 252 patients with gBRCAm were recruited and received at least one dose of olaparib

The most common adverse events requiring emergency treatment

The most common adverse events requiring emergency treatment (TEAE: >20% of patients) are nausea, anemia, weakness, vomiting, and fatigue

In summary, in clinical practice, olapa has good efficacy in gBRCAm and HER2-negative mBC patients, and its safety is consistent with previous research reports

Gelmon Karen A,Fasching Peter A,Couch Fergus J et al.